Literature DB >> 26354426

HPV vaccination syndrome. A questionnaire-based study.

Manuel Martínez-Lavín1, Laura-Aline Martínez-Martínez2, Paola Reyes-Loyola2.   

Abstract

Isolated cases and small series have described the development of complex regional pain syndrome, postural orthostatic tachycardia, and fibromyalgia after human papillomavirus (HPV) vaccination. These illnesses are difficult to diagnose and have overlapping clinical features. Small fiber neuropathy and dysautonomia may play a major role in the pathogenesis of these entities. We used the following validated questionnaires to appraise the chronic illness that might appear after HPV vaccination: The 2010 American College of Rheumatology Fibromyalgia Diagnostic Criteria, COMPASS 31 dysautonomia questionnaire, and S-LANSS neuropathic pain form. These questionnaires and a "present illness" survey were e-mailed to persons who had the onset of a chronic ailment soon after HPV vaccination. Forty-five filled questionnaires from individuals living in 13 different countries were collected in a month's period. Mean (±SD) age at vaccination time was 14 ± 5 years. Twenty-nine percent of the cases had immediate (within 24 h) post-vaccination illness onset. The most common presenting complaints were musculoskeletal pain (66%), fatigue (57%), headache (57%), dizziness/vertigo (43%), and paresthesias/allodynia (36%). Fifty-three percent of affected individuals fulfill the fibromyalgia criteria. COMPASS-31 score was 43 ± 21, implying advanced autonomic dysfunction. Eighty-three percent of the patients who had ongoing pain displayed S-LANSS values >12, suggesting a neuropathic component in their pain experience. After a mean period of 4.2 ± 2.5 years post-vaccination, 93% of patients continue to have incapacitating symptoms and remain unable to attend school or work. In conclusion, a disabling syndrome of chronic neuropathic pain, fatigue, and autonomic dysfunction may appear after HPV vaccination.

Entities:  

Keywords:  Complex regional pain syndrome; Dysautonomia; Fibromyalgia; Gulf War Illness; HPV vaccine; Myalgic encephalomyelitis; Small fiber neuropathy

Mesh:

Substances:

Year:  2015        PMID: 26354426     DOI: 10.1007/s10067-015-3070-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  13 in total

1.  A SCN9A gene-encoded dorsal root ganglia sodium channel polymorphism associated with severe fibromyalgia.

Authors:  Gilberto Vargas-Alarcon; Edith Alvarez-Leon; Jose-Manuel Fragoso; Angelica Vargas; Aline Martinez; Maite Vallejo; Manuel Martinez-Lavin
Journal:  BMC Musculoskelet Disord       Date:  2012-02-20       Impact factor: 2.362

2.  Suspected side effects to the quadrivalent human papilloma vaccine.

Authors:  Louise Brinth; Ann Cathrine Theibel; Kirsten Pors; Jesper Mehlsen
Journal:  Dan Med J       Date:  2015-04       Impact factor: 1.240

3.  Fibromyalgia-like illness in 2 girls after human papillomavirus vaccination.

Authors:  Manuel Martínez-Lavín
Journal:  J Clin Rheumatol       Date:  2014-10       Impact factor: 3.517

4.  Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine.

Authors:  Tomomi Kinoshita; Ryu-Ta Abe; Akiyo Hineno; Kazuhiro Tsunekawa; Shunya Nakane; Shu-Ichi Ikeda
Journal:  Intern Med       Date:  2014       Impact factor: 1.271

5.  The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity.

Authors:  Frederick Wolfe; Daniel J Clauw; Mary-Ann Fitzcharles; Don L Goldenberg; Robert S Katz; Philip Mease; Anthony S Russell; I Jon Russell; John B Winfield; Muhammad B Yunus
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

6.  [Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007-2011)].

Authors:  M A Rodríguez-Galán; S Pérez-Vilar; J Díez-Domingo; J Tuells; J Gomar-Fayos; F Morales-Olivas; E Pastor-Villalba
Journal:  An Pediatr (Barc)       Date:  2014-02-26       Impact factor: 1.500

7.  COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score.

Authors:  David M Sletten; Guillermo A Suarez; Phillip A Low; Jay Mandrekar; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2012-12       Impact factor: 7.616

8.  Postural tachycardia syndrome following human papillomavirus vaccination.

Authors:  S Blitshteyn
Journal:  Eur J Neurol       Date:  2013-09-16       Impact factor: 6.089

Review 9.  Hypothesis: Human papillomavirus vaccination syndrome--small fiber neuropathy and dysautonomia could be its underlying pathogenesis.

Authors:  Manuel Martínez-Lavín
Journal:  Clin Rheumatol       Date:  2015-05-20       Impact factor: 3.650

Review 10.  Clinical features in patients with long-lasting macrophagic myofasciitis.

Authors:  Muriel Rigolet; Jessie Aouizerate; Maryline Couette; Nilusha Ragunathan-Thangarajah; Mehdi Aoun-Sebaiti; Romain Kroum Gherardi; Josette Cadusseau; François Jérôme Authier
Journal:  Front Neurol       Date:  2014-11-28       Impact factor: 4.003

View more
  16 in total

1.  Re: Proposed HPV vaccination syndrome is unsubstantiated.

Authors:  Manuel Martínez-Lavin
Journal:  Clin Rheumatol       Date:  2015-11-14       Impact factor: 2.980

2.  Proposed HPV vaccination syndrome is unsubstantiated.

Authors:  Helen Petousis-Harris
Journal:  Clin Rheumatol       Date:  2015-10-21       Impact factor: 2.980

3.  Response to Dr. Hawkes letter regarding HPV vaccine serious adverse events.

Authors:  Manuel Martínez-Lavín
Journal:  Clin Rheumatol       Date:  2017-04-18       Impact factor: 2.980

4.  Vaccine-related serious adverse events might have been under-recognized in the pivotal HPV vaccine randomized trial.

Authors:  Manuel Martínez-Lavín
Journal:  Clin Rheumatol       Date:  2017-02-16       Impact factor: 2.980

5.  Comment on: "Safety of Human Papillomavirus Vaccines: An Updated Review".

Authors:  Manuel Martínez-Lavín
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

Review 6.  Safety of Human Papillomavirus Vaccines: An Updated Review.

Authors:  Anastasia Phillips; Cyra Patel; Alexis Pillsbury; Julia Brotherton; Kristine Macartney
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

Review 7.  Autonomic dysfunction and HPV immunization: an overview.

Authors:  Svetlana Blitshteyn; Louise Brinth; Jeanne E Hendrickson; Manuel Martinez-Lavin
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

Review 8.  Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series.

Authors:  Manuel Martínez-Lavín; Luis Amezcua-Guerra
Journal:  Clin Rheumatol       Date:  2017-07-20       Impact factor: 3.650

Review 9.  Recommendations and barriers to vaccination in systemic lupus erythematosus.

Authors:  Megha Garg; Naaima Mufti; Tara N Palmore; Sarfaraz A Hasni
Journal:  Autoimmun Rev       Date:  2018-08-11       Impact factor: 9.754

Review 10.  Novel vaccine safety issues and areas that would benefit from further research.

Authors:  Daniel A Salmon; Paul Henri Lambert; Hanna M Nohynek; Julianne Gee; Umesh D Parashar; Jacqueline E Tate; Annelies Wilder-Smith; Kenneth Y Hartigan-Go; Peter G Smith; Patrick Louis F Zuber
Journal:  BMJ Glob Health       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.